Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT00165490
Phase
PHASE2
Status
Completed

Conditions

  • Adenocarcinoma of Esophagus
  • Squamous Cell Carcinoma of Esophagus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cetuximab — DRUG
    Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
  • Cisplatin — DRUG
    Given once per week on weeks 1, 2, 4,and 5.
  • Irinotecan — DRUG
    Given once per week on weeks 1, 2, 4,and 5.
  • Radiation therapy — DEVICE
    Once daily for 28 treatments (5 1/2 weeks)
  • Surgery — PROCEDURE
    Surgery performed 4-8 weeks after chemoradiation therapy.

Study Details

The purpose of this study is to find out what effects (good and bad) the combination of three chemotherapy drugs (cetuximab, cisplatin, and irinotecan) have on esophageal cancer when given with radiation therapy.

Key Dates

Start date
Aug 31, 2004
Status verified
Nov 2014
Primary completion
Nov 30, 2007
Completion
Nov 30, 2014

Study Design

Enrollment
19 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma. [ Time Frame: 3 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02115-

Find similar trials in Boston, MA

By research site
Dana-Farber Cancer Institute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies